Viking Therapeutics, Inc. (VKTX)
$12.88
Rating:
Recommendation:
Buy
| Symbol | VKTX |
|---|---|
| Price | $12.88 |
| Beta | 0.516 |
| Volume Avg. | 2.06M |
| Market Cap | 1.288B |
| Shares () | - |
| 52 Week Range | 2.535-25.72 |
| 1y Target Est | - |
| DCF Unlevered | VKTX DCF -> | |
|---|---|---|
| DCF Levered | VKTX LDCF -> | |
| ROE | -35.23% | Strong Sell |
| ROA | -17.95% | Sell |
| Operating Margin | - | |
| Debt / Equity | 0.37% | Neutral |
| P/E | -14.31 | Strong Sell |
| P/B | 3.30 | Strong Buy |
Latest VKTX news
About
Download (Excel)Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.